Radiofarmacos no Tratamento da dor metastica óssea, estado da arte e perspectivas

Abstract

Introduction: Painful metastatic bone disease is responsible for more than 99% of malignant tumors that affect bone tissue. The treatment involves the use of medication, and one possibility would be the use of radiopharmaceuticals and/or radioisotopes, but with little diffusion. Method: A bibliographic search was carried out from 2010 to 2020, with cancer, bone metastasis, radioisotopes, radioisotopes and radiopharmaceuticals descriptors in the treatment of bone pain both in our language and with correspondence in English and their associations. Results: It was observed that several radiopharmaceuticals and/or radioisotopes that are already available in other countries are not yet available in our country. The use of radiopharmaceuticals and/or radioisotopes could increase the quality of life of individuals affected by this disease, in addition to the development of science in this area since it is multidisciplinary and a matter of individualized medicine. Discussion: It is perceived several studies outside the national territory, demonstrating the efficacy in the use of various radiopharmaceuticals and/or radioisotopes. Closely watched out to the basic physical properties so that you can have a better treatment effectiveness. Also emphasizing that the administered radiation doses in each case must be controlled so that the benefits are effective. Conclusion: The use of new radiopharmaceuticals and/or radioisotopes for the treatment of painful metastatic bone disease may be an available option provided that production issues and current existing legislation are adjusted.